Stockscreener 앱 받기
2.27
0.89%
0.02
시장 영업 전:
2.34
0.07
+3.08%
전일 마감가:
$2.25
열려 있는:
$2.37
하루 거래량:
2.15M
Relative Volume:
3.97
시가총액:
$178.18M
수익:
-
순이익/손실:
$1.60M
주가수익비율:
75.67
EPS:
0.03
순현금흐름:
$-62.91M
1주 성능:
+13.50%
1개월 성능:
+48.37%
6개월 성능:
+24.73%
1년 성능:
+17.01%
1일 변동 폭
$2.13
$2.45
1주일 범위
$1.92
$2.45
52주 변동 폭
$1.35
$3.0301
Compugen Ltd Stock (CGEN) Company Profile
CGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.27 | 178.18M | 0 | 1.60M | -62.91M | 0.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 개시 | Oppenheimer | Outperform |
| 2022-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-26 | 재개 | JMP Securities | Mkt Outperform |
| 2020-05-13 | 개시 | Stifel | Buy |
| 2020-05-07 | 개시 | SVB Leerink | Outperform |
| 2020-04-22 | 개시 | ROTH Capital | Buy |
| 2020-03-24 | 개시 | SunTrust | Buy |
| 2020-01-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-29 | 개시 | Oppenheimer | Outperform |
| 2016-02-01 | 재개 | Oppenheimer | Outperform |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2015-04-23 | 재개 | Jefferies | Buy |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-02-07 | 개시 | MLV & Co | Buy |
| 2009-12-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2009-07-29 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Compugen Ltd 주식(CGEN)의 최신 뉴스
Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - Simply Wall St
Compugen (NASDAQ:CGEN) Now Covered by Oppenheimer - Defense World
Compugen Ltd (NASDAQ: CGEN) Gains 3.14% In Early Trade; What Lies Ahead? - Stocks Register
Oppenheimer Initiates Coverage on Compugen (NASDAQ:CGEN) - MarketBeat
Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential By Investing.com - Investing.com Australia
Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential - Investing.com India
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - Marketscreener.com
Compugen Launches First-in-Class Cancer Trial with Novel IL-18 Antibody COM503 - StockTitan
Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy - AOL
The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable - Yahoo Finance
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Gilead Sciences Inc (GILD-Q) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World
Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks
Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World
Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat
Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance
Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com
Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... - Yahoo Finance
Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... By GuruFocus - Investing.com Canada
Compugen Reports Strong Q3 2024 Results and Progress - TipRanks
Compugen: Q3 Earnings Snapshot - The Washington Post
Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates - Yahoo Canada Finance
Compugen earnings beat by $0.11, revenue topped estimates - Investing.com India
Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compugen Surges with $17.1M Revenue, Reports Breakthrough Cancer Drug Progress - StockTitan
Compugen to Participate in Stifel 2024 Healthcare Conference - StockTitan
Compugen (CGEN) to Release Quarterly Earnings on Tuesday - Defense World
Compugen (NASDAQ:CGEN) shareholder returns have been stellar, earning 204% in 1 year - Simply Wall St
Compugen Showcases Promising Data on Ovarian Cancer Therapy - TipRanks
Compugen's Cancer Drug Combo Shows 17.4% Response Rate in Ovarian Cancer Trial | CGEN Stock News - StockTitan
Short Interest in Compugen Ltd. (NASDAQ:CGEN) Decreases By 17.1% - MarketBeat
Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - cnhinews.com
Compugen Gears Up to Report Q3 Earnings: Here's What to Expect - Yahoo Finance
Compugen to Present New Clinical Data at SITC 2024 - StockTitan
Compugen Ltd. (NASDAQ:CGEN) Shares Sold by Renaissance Technologies LLC - Defense World
Compugen Ltd (CGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):